摘要
目的探讨恩度联合顺铂治疗晚期非小细胞肺癌的临床效果。方法选择2010年2月～2013年2月在本院肿瘤内科治疗的中晚期非小细胞肺癌患者117例患者，随机分为单纯化疗组（对照组）58例和恩度联合顺铂组（观察组）59例，观察两组患者的临床疗效及不良反应。结果观察组总有效率为59．32％，对照组总有效率为37．93％；两组比较，差异有统计学意义（P〈0．05）。两组不良反应比较，差异无统计学意义（P〉0．05）。结论恩度联合顺铂胸腔内注射治疗晚期非小细胞肺癌临床疗效显著，值得在临床推广应用。
Objective To investigate the clinical Effect of Endostar combined with cisplatin intrapleural injection in the treatment of advanced non-small cell lung cancer. Methods 117 cases of patients withadvanced non small cell lung cancer patients In 2010 February -2013 year in February were collected in the hospital, who were randomly divided into chemotherapy group（control group） 58 cases and Endostar combined with cisplatin group （ observation group ） 59 cases, The clinicalefficacy and adverse reactions of two groups of patients observation were observed. Results The observation group the total effective rate was 59.32%, total effective rate of the control group was 37.93%; the two groups, the difference was statistically significant（P 〈 0.05）. Adverse reactions of two groups, the difference was not statistically significant（P 〉 0.05）. Conclusion Endostar combined with cisplatin intrapleural injection in the treatment of advanced non-small cell lung cancer clinical efficacy significantly, it is worth in clinical application..
出处
《中国医药科学》
2013年第20期47-48,共2页
China Medicine And Pharmacy
关键词
恩度
顺铂
非小细胞肺癌
Endostatin
Cisplatin
Non small cell lung cancer
